Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Haemoglobin levels predict outcomes in nondialysis CKD

01 Oct 2020

In patients with stage 3–5 nondialysis chronic kidney disease (ND-CKD), anaemia appears to worsen health-related quality of life (HRQoL), mortality, and disease progression, a recent study has found.

The study included 2,121 ND-CKD patients (mean age, 68±13 years; 52 percent male) who were divided into three groups according to haemoglobin (Hgb) levels: <10 (n=267), 10-12 (n=843), and >12 (n=947) g/dL. Study outcomes were HRQoL, physical activity, CKD progression, and mortality.

HRQoL was measured using the Kidney Disease Quality of Life 36 (KDQOL-36), and scores were worse in patients with severe anaemia (Hgb <10 g/dL) compared to those with Hgb >10 g/dL. This finding was consistent across the different domains and subdomains of KDQOL-36. Notably, even those with only mild/moderate anaemia (Hgb 10–12 g/dL) showed impaired HRQoL.

Moreover, adjusted spline regression analysis showed that lower Hgb levels significantly decreased the likelihood of a patient being physically active (10.5 vs 12 g/dL: adjusted odds ratio, 0.63, 95 percent confidence interval [CI], 0.42–0.94).

Similarly, lower Hgb (<10 vs >12 g/dL) significantly increased the risk of CKD progression (adjusted hazard ratio [HR], 1.78, 95 percent CI, 1.29–2.47) and death (adjusted HR, 3.13, 95 percent CI, 2.11–4.65). Physical inactivity was likewise a significant risk factor for CKD progression and death.

“Our findings help inform the design of future studies aimed at understanding the effects of anaemia therapies in CKD patients and how anaemia correction may impact improvements in well-being and clinical outcomes,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.